ClinicalTrials.gg
Active, not recruitingNCT06269133Updated Sep 10, 2026

Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Participants

An observational study in Advanced Non-small Cell Lung Cancer, sponsored by Regeneron Pharmaceuticals. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by Regeneron Pharmaceuticals · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
1,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Carcinoma, Non-Small-Cell Lung by Regeneron Pharmaceuticals — 2 open to participants now, 11 under way, 2 of them phase 3. Carcinoma, Non-Small-Cell Lung · Regeneron Pharmaceuticals.

Started
2024
with 2 others
Observational
2 of 21
none open now
Primary completion
2027-03
later than 2 of 10 live
Registered
18th of 21
by date

Among the 21 studies in Carcinoma, Non-Small-Cell Lung by Regeneron Pharmaceuticals, this one is one of 3 that started in 2024, is one of 2 observational ones, reaches primary completion later than 2 of the 10 other live ones, and was the 18th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

2 of the 21 studies in Carcinoma, Non-Small-Cell Lung by Regeneron Pharmaceuticals are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Carcinoma, Non-Small-Cell Lung by Regeneron Pharmaceuticals, or all of them as a file.
02

Study summary

This multi-year cohort study will assess the real-world safety and effectiveness of first Line (1L) treatment with cemiplimab in combination with platinum-doublet chemotherapy across advanced NSCLC participant subgroups defined by age, sex, race, and ethnicity. Participants will be retrospectively identified from at least two US Electronic Health Record (EHR)-based databases.

Read the detailed description

Participants and baseline variables will be captured retrospectively, but outcome measures will be prospectively ascertained.

03

Conditions studied

  • Advanced Non-small Cell Lung Cancer

Keywords

  • Advanced Non-Small Cell Lung Cancer (aNSCLC)
  • Epidermal Growth Factor Receptor (EGFR)
  • Anaplastic Lymphoma Kinase (ALK)
  • C-ros oncogene receptor tyrosine kinase (ROS1)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants with advanced disease, defined as stage IIIB, IIIC, or IV disease, with evidence of administration of 1L cemiplimab in combination with platinum-doublet chemotherapy between 08 Nov 2022 and 30 Jun 2026 and without EGFR, ALK, or ROS1 genomic variants, or actively enrolled in a clinical trial in which they receive treatment with cemiplimab in combination with platinum-doublet chemotherapy.

Eligibility criteria

Key Inclusion Criteria:

1. Advanced non-small cell lung cancer (aNSCLC) (defined as stage IIIB/C or stage IV) treated with cemiplimab in combination with platinum-doublet chemotherapy in the 1L setting from Nov 2022 to Jun 2026 as described in the protocol

Key Exclusion Criteria:

  1. Participants who have EGFR, ALK or ROS1 variants
  2. Treatment with EGFR, ALK or ROS1 inhibitors at any time prior to the index date
  3. Participants actively enrolled in a clinical trial in which they receive treatment with cemiplimab in combination with platinum-doublet chemotherapy

Note: Other protocol-defined Inclusion/ Exclusion Criteria apply

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
1,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Study Participants

    Participants who have received cemiplimab in combination with platinum-doublet chemotherapy for the 1L treatment of aNSCLC in the US with no documented EGFR, ALK and ROS1 variants as described in the protocol.

    Drug: REGN2810 · Other: Platinum-doublet chemotherapy

Interventions

  • DrugCemiplimabStudies of CemiplimabCemiplimab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    No study specific interventions for this non-interventional-observational study; participants had previously been administered this treatment.

    Also known as: LIBTAYO®, cemiplimab

  • OtherPlatinum-doublet chemotherapy

    No study specific interventions for this non-interventional-observational study; participants had previously been administered this treatment.

06

What researchers measure

Primary outcomes

  1. Real-world Response Rate (rwRR)

    Time frame: Approximately 3 years

  2. Any treatment-emergent immune-mediated Adverse Event (imAE)

    Time frame: Approximately 3 years

  3. Any treatment-emergent imAE resulting in hospitalization

    Time frame: Approximately 3 years

  4. Any treatment-emergent imAE resulting in death

    Time frame: Approximately 3 years

  5. Specific treatment-emergent imAEs

    Time frame: Approximately 3 years

Secondary outcomes

  1. Real-world Duration Of Response (rwDOR)

    Time frame: Approximately 3 years

  2. Real-world Progression-Free survival (rwPFS)

    Time frame: Approximately 3 years

  3. Real-world Overall Survival (rwOS)

    Time frame: Approximately 3 years

  4. imAEs

    Time frame: Approximately 3 years

  5. Infusion-Related Reaction (IRR)

    Time frame: Approximately 3 years

  6. IRR resulting in hospitalization

    Time frame: Approximately 3 years

  7. IRR resulting in death

    Time frame: Approximately 3 years

07

Study locations

1 site
  • Regeneron Research Facility
    Tarrytown, New York 10591, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Mar 2027, 37 months after the start.

Of 142 industry-sponsored observational studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 64. This study's planned 37 months is below that.

Counting every sponsor, half of 500 studies reached it within 55 months; a quarter within 35 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2024
First posted
Feb 21, 2024
StartActual
Feb 21, 2024
Primary completionEst.
Mar 31, 2027
CompletionEst.
Mar 31, 2027
Last update
Sep 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06269133
Responsible party
Sponsor
First posted
Feb 21, 2024
Start date
Feb 21, 2024
Primary completion
Mar 31, 2027 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Sep 10, 2026

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion